First Turn Management as of Sept. 30, 2025
Portfolio Holdings for First Turn Management
First Turn Management holds 29 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Insmed Com Par $.01 (INSM) | 6.9 | $46M | 320k | 144.01 | |
| Mirum Pharmaceuticals (MIRM) | 6.3 | $42M | 571k | 73.31 | |
| United Therapeutics Corporation (UTHR) | 5.4 | $36M | 85k | 419.21 | |
| Merus N V (MRUS) | 5.3 | $35M | 372k | 94.15 | |
| Nuvalent Inc-a (NUVL) | 5.1 | $34M | 395k | 86.48 | |
| Xenon Pharmaceuticals (XENE) | 4.8 | $32M | 800k | 40.15 | |
| Bridgebio Pharma (BBIO) | 4.6 | $31M | 590k | 51.94 | |
| Revolution Medicines (RVMD) | 4.5 | $30M | 643k | 46.70 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 4.4 | $29M | 146k | 198.81 | |
| Argenx Se Sponsored Adr (ARGX) | 4.3 | $29M | 39k | 737.56 | |
| Disc Medicine (IRON) | 3.9 | $26M | 398k | 66.08 | |
| Oric Pharmaceuticals (ORIC) | 3.9 | $26M | 2.2M | 12.00 | |
| Arcellx Common Stock (ACLX) | 3.9 | $26M | 314k | 82.10 | |
| Neurocrine Biosciences (NBIX) | 3.8 | $26M | 182k | 140.38 | |
| Abivax Sa Sponsored Ads (ABVX) | 3.7 | $25M | 292k | 84.90 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 3.1 | $20M | 717k | 28.44 | |
| Akero Therapeutics (AKRO) | 2.8 | $19M | 397k | 47.48 | |
| Axsome Therapeutics (AXSM) | 2.8 | $19M | 153k | 121.45 | |
| Enliven Therapeutics (ELVN) | 2.4 | $16M | 783k | 20.47 | |
| Apogee Therapeutics (APGE) | 2.4 | $16M | 403k | 39.73 | |
| Kymera Therapeutics (KYMR) | 2.4 | $16M | 278k | 56.60 | |
| Janux Therapeutics (JANX) | 2.3 | $16M | 640k | 24.44 | |
| Roivant Sciences SHS (ROIV) | 2.2 | $15M | 960k | 15.13 | |
| Cytokinetics Com New (CYTK) | 2.1 | $14M | 255k | 54.96 | |
| Natera (NTRA) | 2.0 | $13M | 81k | 160.97 | |
| Adma Biologics (ADMA) | 1.8 | $12M | 809k | 14.66 | |
| Vera Therapeutics Cl A (VERA) | 1.5 | $10M | 355k | 29.06 | |
| Harrow Health (HROW) | 1.2 | $7.7M | 160k | 48.18 | |
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.3 | $1.9M | 263k | 7.17 |
